Clinical trials
Breast cancer clinical trials
Cancer that forms in the cells of the breast, the most common cancer in women. We’re tracking 2,417 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05846789RecruitingPhase 2
Tocilizumab plus chemo for metastatic breast cancer
This trial tests whether adding tocilizumab, a drug that calms the immune system, to standard chemotherapy helps control certain advanced breast cancers. It is for people with triple-negative or ER-positive, HER2-negative breast cancer that has spread or come back.
Atlanta, GeorgiaAges 18 years+ - NCT05837455RecruitingPhase 2
Biomarker-guided treatment for early breast cancer before surgery
This trial looks at whether using tumor test results (biomarkers) can help guide the best hormone treatment and chemotherapy before surgery. It focuses on people with stage II or III, ER-positive, HER2-negative breast cancer, with the goal of improving how well the tumor responds before it is removed.
St Louis, MissouriAges 18 years+ - NCT05817227Recruiting
Study of selenium-related markers in triple-negative breast cancer
This study looks at “selenoproteins” (protein markers in the body) to understand how triple-negative breast cancer behaves and whether they could be targets for future treatments. You may be asked to provide samples before any cancer drug treatment to see if these markers predict outcomes.
Naples, NapoliAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Birmingham, AlabamaAges 18 years+ - NCT05786664Recruiting
Breast cancer survivor study collecting your health samples
This study invites women who finished treatment for non-metastatic invasive breast cancer to share health information and biological samples for future research. It may help scientists understand survivorship and improve care after treatment.
Los Angeles, CaliforniaAges 18 years+ - NCT05795101RecruitingPhase 2
TRUDI trial for inflammatory breast cancer with HER2/low markers
This Phase 2 trial tests two medicines—durvalumab and trastuzumab deruxtecan—to treat stage III inflammatory breast cancer. It may help by controlling cancer growth using treatments aimed at specific breast cancer markers (HER2 positive or “HER2-low”).
Boston, MassachusettsAges 18 years+ - NCT05780814Recruiting
Treating insomnia to improve weight loss after breast cancer
This study looks at whether improving insomnia (trouble falling asleep or staying asleep) can help survivors of breast cancer lose weight more successfully through a structured behavioral weight loss program. It may help if sleep problems are making it harder to change eating and activity habits.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05774951RecruitingPhase 3
Camizestrant for hormone-positive, HER2-negative early breast cancer
This trial tests camizestrant, a medicine that blocks estrogen signaling, to help prevent hormone-positive, HER2-negative early breast cancer from coming back. You may be eligible if your cancer has higher- or intermediate-risk features and you already completed at least 2 years of hormone therapy.
Birmingham, AlabamaAges 18–130 - NCT05748834RecruitingPhase 2
Tucatinib plus Doxil for HER2-positive metastatic breast cancer
This Phase 2 study tests tucatinib (a HER2-targeted pill) plus Doxil (a chemotherapy medicine) to slow or shrink HER2-positive metastatic breast cancer that has been treated before. It may help by targeting HER2 cancer cells more effectively than past treatments alone.
Columbia, MarylandAges 18 years+ - NCT04074720Recruiting
Collecting breast cancer tissue and blood samples
This study collects tissue and/or blood samples from people with breast cancer to help future research. It may be useful if you’re already having surgery or another procedure as part of your treatment plan.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Orlando, FloridaAges 18 years+ - NCT05741164RecruitingPhase 2
Propranolol plus pembrolizumab for hard-to-treat breast cancer
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
Atlanta, GeorgiaAges 18 years+ - NCT05716893RecruitingPhase 2
Aerobic exercise program for people getting breast cancer treatment
This Phase 2 study tests whether a supervised aerobic (cardio) training program can improve health and exercise capacity for people receiving treatment for primary breast cancer. You may join if you currently do very little moderate-to-vigorous exercise and can safely complete a special treadmill test that measures breathing and heart response.
Basking Ridge, New JerseyAges 18 years+ - NCT05736367Recruiting
Study tumor metabolism in certain types of breast cancer surgery
This study looks at how breast cancer cells use energy and nutrients in hormone-receptor positive, HER2-negative tumors during planned surgery. It may help researchers understand the cancer better by comparing tumor tissue with nearby normal tissue.
New Brunswick, New JerseyAges 18 years+ - NCT05677802Recruiting
Stress-reduction program for newly diagnosed triple-negative breast cancer
This study tests whether a structured stress-reduction program can help people with newly diagnosed triple-negative breast cancer (stages I–III). The goal is to see if the program is practical and beneficial for patients during treatment.
Cleveland, OhioAges 18 years+ - NCT05660083RecruitingPhase 2
Study of alpelisib plus iNOS inhibitor with nab-paclitaxel
This Phase 2 trial tests whether a combination of medicines can shrink and control HER2-negative metaplastic breast cancer that cannot be removed with surgery (locally advanced) or has spread (metastatic). It may help people whose cancer has specific lab/pathology features, and it also checks safety and how well the treatment works in the body.
Bethesda, MarylandAges 18 years+ - NCT05659797RecruitingEarly Phase 1
PET scan test for new ER-positive breast cancer
This early study tests a special PET scan (a type of imaging) to look at newly diagnosed ER-positive breast cancer. The goal is to see how well the scan can detect and measure cancer, which may help guide care.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05652569Recruiting
Genomics-guided treatment plan for metastatic breast cancer
This trial tests a personalized treatment approach for people with metastatic (advanced spread) breast cancer using tumor testing. It may help guide doctors toward better-matched therapies based on genomic (DNA) information from your tumor.
AugsburgAges 14–100 - NCT05667532Recruiting
Contrast mammogram screening for women with dense breasts
This study tests how well a special mammogram with contrast can help assess breast cancer risk in women with dense breast tissue. It may help improve screening planning, especially when standard mammograms are harder to read due to density.
Houston, TexasAges 30–75 - NCT05601440RecruitingPhase 2
Trial for metastatic breast cancer that resisted CDK4/6 treatment
This Phase 2 study tests treatments guided by blood testing (“liquid biopsy”) in people with hormone receptor–positive, HER2-negative metastatic breast cancer that has progressed after standard CDK4/6 medicine plus hormone therapy. It aims to find a better way to control cancer after the first treatment stops working.
Calgary, AlbertaAges Any age - NCT05595499RecruitingPhase 2
Fisetin for better walking and strength in breast cancer survivors
This study tests whether fisetin (a natural compound) can improve physical function, like walking ability, in breast cancer survivors who feel frail. It may help strengthen muscles and improve daily activity after treatment.
Alhambra, CaliforniaAges Any age - NCT05608252RecruitingPhase 1/Phase 2
Drug combination for advanced ER-positive, HER2-negative breast cancer
This Phase 1/2 study tests how well a new treatment combination (VS-6766, abemaciclib, and fulvestrant) works for metastatic or hard-to-remove breast cancer that is hormone-driven (ER/PR positive) and HER2 negative. It is mainly designed to find the safest dose and then see whether it can control the cancer after it has progressed on certain prior medicines.
Boston, MassachusettsAges 18 years+ - NCT05621564Recruiting
Pre-surgery treatment for women with breast cancer
This trial studies a treatment given before surgery for people with breast cancer. It may help shrink or control the cancer before an operation, depending on what the study drug or approach is.
ShanghaiAges 18 years+ - NCT05592938Recruiting
Partial breast re-irradiation for cancer recurrence
This trial tests a shorter course of radiation to only the part of the breast where cancer has come back. It's for women who had radiation years ago and now have a small new or recurrent tumor that can be removed by surgery.
New York, New YorkAges 18–99
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer?
- Yes. Clin2 currently lists 2,417 recruiting breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.